ATE179718T1 - Peptidsequenzen, spezifisch für die hepatitische phase von p. falciparum, epitope tragend; die die fähigkeit besitzen, die t-lymphozyten anzuregen - Google Patents

Peptidsequenzen, spezifisch für die hepatitische phase von p. falciparum, epitope tragend; die die fähigkeit besitzen, die t-lymphozyten anzuregen

Info

Publication number
ATE179718T1
ATE179718T1 AT92905897T AT92905897T ATE179718T1 AT E179718 T1 ATE179718 T1 AT E179718T1 AT 92905897 T AT92905897 T AT 92905897T AT 92905897 T AT92905897 T AT 92905897T AT E179718 T1 ATE179718 T1 AT E179718T1
Authority
AT
Austria
Prior art keywords
falciparum
peptide sequences
molecule
hepatitic
lymphocytes
Prior art date
Application number
AT92905897T
Other languages
English (en)
Inventor
Claudine Guerin-Marchand
Pierre Druilhe
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE179718T1 publication Critical patent/ATE179718T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/822—Protozoa

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT92905897T 1991-02-05 1992-02-05 Peptidsequenzen, spezifisch für die hepatitische phase von p. falciparum, epitope tragend; die die fähigkeit besitzen, die t-lymphozyten anzuregen ATE179718T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9101286A FR2672290B1 (fr) 1991-02-05 1991-02-05 Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.

Publications (1)

Publication Number Publication Date
ATE179718T1 true ATE179718T1 (de) 1999-05-15

Family

ID=9409373

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92905897T ATE179718T1 (de) 1991-02-05 1992-02-05 Peptidsequenzen, spezifisch für die hepatitische phase von p. falciparum, epitope tragend; die die fähigkeit besitzen, die t-lymphozyten anzuregen

Country Status (10)

Country Link
US (5) US6319502B1 (de)
EP (1) EP0570489B1 (de)
AT (1) ATE179718T1 (de)
CA (3) CA2101924C (de)
DE (1) DE69229107T2 (de)
DK (1) DK0570489T3 (de)
ES (1) ES2133316T3 (de)
FR (1) FR2672290B1 (de)
GR (1) GR3030219T3 (de)
WO (1) WO1992013884A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672290B1 (fr) 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
US20030161840A1 (en) * 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
FR2735478B1 (fr) 1995-06-13 1997-08-22 Pasteur Institut Molecules polypeptidiques de stade pre-erythrocytaire du paludisme
ATE534669T1 (de) * 2002-05-28 2011-12-15 Omrix Biopharmaceuticals Inc Verfahren zum erhalten von anti-idiotyp antikörpern
WO2004044167A2 (en) * 2002-11-12 2004-05-27 Walter Reed Army Institute Of Research Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide
KR101035111B1 (ko) * 2004-06-30 2011-05-19 주식회사 엘지생명과학 말라리아 플라스모듐 팔시파룸의 면역학적 측정방법 및이에 사용되는 측정 수단
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EA020950B1 (ru) 2007-09-17 2015-03-31 Баррик Гольд Корпорейшн Способ усовершенствования восстановления золота из двойных тугоплавких золотосодержащих руд
US8262770B2 (en) 2007-09-18 2012-09-11 Barrick Gold Corporation Process for controlling acid in sulfide pressure oxidation processes
US7922788B2 (en) * 2007-09-18 2011-04-12 Barrick Gold Corporation Process for recovering gold and silver from refractory ores
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
CN103491979B (zh) 2010-12-06 2016-12-21 马尔瓦有限责任公司 基于来自恶性疟原虫的红细胞前期抗原的疟疾疫苗
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
KR20250008135A (ko) 2016-06-01 2025-01-14 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
CA3141577A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU569722B2 (en) * 1983-01-28 1988-02-18 Saramane Pty Ltd Expression of plasmodium falciparum polypeptides from cloned cdna
IL76338A (en) * 1984-09-11 1994-08-26 Saramane Pty Ltd Plasmodium plasmodium immunogenic polypeptides, AND molecules encoding them, a method for preparing the polypeptides and preparations containing the polypeptide
IL78476A0 (en) * 1985-04-11 1986-08-31 Inst Medical W & E Hall Highly repetitive antigens of plasmodium falciparum
EP0297110A4 (de) * 1986-03-14 1989-12-19 Saramane Pty Ltd Polypeptide mit immunwirkung gegen malaria.
FR2672290B1 (fr) * 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
US6270771B1 (en) * 1988-10-06 2001-08-07 Institut Pasteur Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes
FR2610631B1 (fr) * 1987-02-09 1989-11-24 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme
AU4661889A (en) * 1988-11-30 1990-06-26 Biomedical Research Institute A novel malarial sporozoite and exoerythrocytic peptide antigen
FR2645877B1 (fr) * 1989-04-12 1991-07-05 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un, ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum au niveau du stade sporozoite et dans les hepatocytes
GB9020438D0 (en) * 1990-09-19 1990-10-31 Imperial College Plasmodium liver stage antigens
US6689363B1 (en) * 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
US5602831A (en) * 1995-03-31 1997-02-11 Seiko Communications Systems, Inc. Optimizing packet size to eliminate effects of reception nulls
FR2735478B1 (fr) * 1995-06-13 1997-08-22 Pasteur Institut Molecules polypeptidiques de stade pre-erythrocytaire du paludisme
CN1244126A (zh) * 1997-01-21 2000-02-09 纽约大学 用于抗疟疾疫苗的通用t细胞表位
CA2337754C (en) * 1998-08-21 2011-05-24 Altaf A. Lal Recombinant multivalent malarial vaccine against plasmodium falciparum
EP1201250A1 (de) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenische Zusammensetzung die hepatische Phaseantigene aus Plasmodium enthält
WO2002092628A2 (fr) * 2001-05-16 2002-11-21 Institut Pasteur Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques
US20050108791A1 (en) * 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
AU2003285932A1 (en) * 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria

Also Published As

Publication number Publication date
FR2672290B1 (fr) 1995-04-21
HK1014012A1 (en) 1999-09-17
EP0570489B1 (de) 1999-05-06
WO1992013884A1 (fr) 1992-08-20
ES2133316T3 (es) 1999-09-16
GR3030219T3 (en) 1999-08-31
EP0570489A1 (de) 1993-11-24
US20030064075A1 (en) 2003-04-03
FR2672290A1 (fr) 1992-08-07
DE69229107T2 (de) 1999-12-16
US20020041882A1 (en) 2002-04-11
US6319502B1 (en) 2001-11-20
CA2101924A1 (fr) 1992-08-06
US7087231B2 (en) 2006-08-08
US20080213795A1 (en) 2008-09-04
CA2101924C (fr) 2005-06-28
US7332595B2 (en) 2008-02-19
CA2495581C (fr) 2008-10-21
US20060182769A1 (en) 2006-08-17
US7438917B2 (en) 2008-10-21
CA2495581A1 (fr) 1992-08-20
DK0570489T3 (da) 2000-01-03
CA2638662A1 (fr) 1992-08-20
DE69229107D1 (de) 1999-06-10

Similar Documents

Publication Publication Date Title
ATE179718T1 (de) Peptidsequenzen, spezifisch für die hepatitische phase von p. falciparum, epitope tragend; die die fähigkeit besitzen, die t-lymphozyten anzuregen
CA2290485A1 (en) Method for the production of non-immunogenic proteins
DE3787460D1 (de) Schimärische peptide für die lieferung von neuropeptiden durch die blut-hirn-grenze.
DE68913970D1 (de) Schimärische peptide für die lieferung von neuropeptiden durch die blut-hirn-barriere.
BR9106220A (pt) Antigenos sinteticos para a deterccao de anticorpos para o virus da hepatite c.
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
DK0561907T3 (da) Proteiner med ændrede epitoper og fremgangsmåder til fremstilling deraf
AU1342888A (en) Molecules comprising at least one peptidic sequence carrying one or a plurality of epitopes characterizing a protein produced by P.Falciparum in hepatocytes and compositions containing them
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
SG95574A1 (en) Immunoreactive antigens of hepatitia e virus
ATE230418T1 (de) Monoklonaler antikörper gegen das humane mx- protein mxa
DE3667061D1 (en) New protein isolated from blood, process for preparing said protein, antibodies against said new protein, and pharmaceutical compositions containing said protein or said antibodies
EP0293827A3 (de) Probe für Leishmaniosis
DE69018325D1 (de) Antigen-Protein der Sporozoit- und hepatischen Phase von P. falciparum.
ES2011679A6 (es) Procedimiento para la preparacion de polipeptidos sinteticos secuenc iales inmunologicamente activos.
KR970707161A (ko) 동종 및 이종 단백질에 대한 항체, 그 항체를 이용한 진단 및 치료 방법 및 그 항체의 측정 방법(antibodies against allogenic and xenogenic proteins, their use in diagnosis and therapy and methods for the determination thereof)
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
JPS6490197A (en) Peptide
Brunner Mapping of two linear epitopes on the G1 glycoprotein of La Crosse virus.
WO2000052056A3 (en) Anti-plasmodium compositions and methods of use
TH65071A (th) เพพไทด์ควบคุม และอนุเคราะห์ hiv แอนติเจน องค์ประกอบวัคซีนชุดสำเร็จรูปอิมมูโนแอสเสย์และวิธีการของการตรวจหาแอนติบอดีที่ถูกชักนำโดย hiv
TH3933A (th) วัคซีนที่มีขอบเขตของการออกฤทธิ์กว้างที่ใช้ต่อต้านโรคโกโนเรีย
SG145521A1 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus
IT9067703A0 (it) Peptidi sintetici contenenti sequenze di aminoacidi che definiscono epitopi immunoreattivi contro anticorpi umani anti hcv, utili per l'alletimento di dosaggi immunologici.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee